X-Biotix Therapeutics, Inc. Strengthens Leadership Team with Key Appointments
Announces Additions of Dr. David N. Cook to Board of Directors and Dr. Boudewijn DeJonge to Leadership Team WALTHAM, Mass.–(BUSINESS…
Pharmaceuticals, Biotechnology and Life Sciences
Announces Additions of Dr. David N. Cook to Board of Directors and Dr. Boudewijn DeJonge to Leadership Team WALTHAM, Mass.–(BUSINESS…
TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain…
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today that it has signed a patent license agreement (the…
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today that it has signed a patent license agreement (the…
Dose escalation phase of the study completed up to the maximum planned dose of 20 mg/kg without dose-limiting toxicities (DLT)…
Dose escalation phase of the study completed up to the maximum planned dose of 20 mg/kg without dose-limiting toxicities (DLT)…
DUBLIN–(BUSINESS WIRE)–The “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2019 in Pharmaceuticals” report has been added to…
DUBLIN–(BUSINESS WIRE)–The “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2019 in Pharmaceuticals” report has been added to…
Submission Follows Productive Pre-NDA Meeting and Marks On-time Execution of First of Two NDA Submissions Planned for 2019 CAMBRIDGE, Mass.–(BUSINESS…
DUBLIN–(BUSINESS WIRE)–The “Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes” report has been added to…